RxSight, Inc.

As of September 30, 2026, RxSight, Inc. carries a market capitalization of 205.44M, placing it among publicly traded companies globally. Its enterprise value stands at -38.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

RxSight, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

As of September 30, 2026, RxSight, Inc. has 41.93M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 1.67, and the price-to-book ratio stands at 0.81.

As of September 30, 2026, RxSight, Inc. maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.05, indicating elevated leverage, while an interest coverage ratio of -4,131.50 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2026, RxSight, Inc. posted a negative return on equity (ROE) of -20.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.44, reflecting losses generated across the asset base. The company generates approximately 264,268.98 in revenue per employee across its workforce of 461.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.85 indicates how many times RxSight, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, RxSight, Inc. recorded 127,000.00 in income tax expense. The company reported a pretax loss of -53.23M and -53.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 6, 2026, RxSight, Inc.'s stock has declined approximately 47.27% over the past 52 weeks. The 50-day moving average sits at 5.22, while the 200-day moving average is 6.24.

Over the twelve months ended September 30, 2026, RxSight, Inc. generated 121.83M in revenue and converted that into -53.36M in net income, yielding earnings per share of -1.29. EBITDA reached -57.84M, while operating income came in at -61.45M.

As of September 30, 2026, RxSight, Inc. holds 254.68M in cash and equivalents against 10.32M in total debt, resulting in a net debt position of -66.72M. Total book value stands at 254.91M, with working capital of 239.85M providing operational flexibility.

RxSight, Inc. produced 23.67M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -5.03M in capital expenditures, free cash flow totaled 18.65M - equivalent to 0.45 per share.

Over the twelve months ended September 30, 2026, RxSight, Inc. posted a gross margin of 76.13, reflecting its pricing power and cost economics. The operating margin of -50.44 and net profit margin of -43.80 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 9.19, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.77, meaning RxSight, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2026, RxSight, Inc. has an Altman Z-Score of -0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.